These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31741766)

  • 1. HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma.
    Malissen N; Macagno N; Granjeaud S; Granier C; Moutardier V; Gaudy-Marqueste C; Habel N; Mandavit M; Guillot B; Pasero C; Tartour E; Ballotti R; Grob JJ; Olive D
    Oncoimmunology; 2019; 8(12):e1665976. PubMed ID: 31741766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer.
    Demerlé C; Gorvel L; Olive D
    Front Oncol; 2021; 11():682007. PubMed ID: 34532285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
    Ren S; Tian Q; Amar N; Yu H; Rivard CJ; Caldwell C; Ng TL; Tu M; Liu Y; Gao D; Ellison K; Suda K; Rozeboom L; Rivalland G; Mitchell P; Zhou C; Hirsch FR
    Lung Cancer; 2018 Nov; 125():115-120. PubMed ID: 30429008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B- and T-Lymphocyte Attenuator in Systemic Lupus Erythematosus Disease Pathogenesis.
    Vendel AC; Jaroszewski L; Linnik MD; Godzik A
    Clin Pharmacol Ther; 2024 Jul; 116(1):247-256. PubMed ID: 38676311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The intrahepatic expression and distribution of BTLA and its ligand HVEM in patients with HBV-related acute-on-chronic liver failure.
    Xu H; Cao D; Guo G; Ruan Z; Wu Y; Chen Y
    Diagn Pathol; 2012 Oct; 7():142. PubMed ID: 23067542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties.
    Haymaker CL; Wu RC; Ritthipichai K; Bernatchez C; Forget MA; Chen JQ; Liu H; Wang E; Marincola F; Hwu P; Radvanyi LG
    Oncoimmunology; 2015 Aug; 4(8):e1014246. PubMed ID: 26405566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis.
    Lan X; Li S; Gao H; Nanding A; Quan L; Yang C; Ding S; Xue Y
    Onco Targets Ther; 2017; 10():919-926. PubMed ID: 28243127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting BTLA with the peptide inhibitor HVEM(14-39) - A new way to restore the activity of T cells in melanoma.
    Wojciechowicz K; Kuncewicz K; Rutkowski J; Jassem J; Rodziewicz-Motowidło S; Wardowska A; Spodzieja M
    Biomed Pharmacother; 2024 Jun; 175():116675. PubMed ID: 38733770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation-Design, Synthesis, and Cellular Studies.
    Kuncewicz K; Battin C; Sieradzan A; Karczyńska A; Orlikowska M; Wardowska A; Pikuła M; Steinberger P; Rodziewicz-Motowidło S; Spodzieja M
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herpes Simplex Virus 1 Latency and the Kinetics of Reactivation Are Regulated by a Complex Network of Interactions between the Herpesvirus Entry Mediator, Its Ligands (gD, BTLA, LIGHT, and CD160), and the Latency-Associated Transcript.
    Wang S; Ljubimov AV; Jin L; Pfeffer K; Kronenberg M; Ghiasi H
    J Virol; 2018 Dec; 92(24):. PubMed ID: 30282707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding.
    Spodzieja M; Kuncewicz K; Sieradzan A; Karczyńska A; Iwaszkiewicz J; Cesson V; Węgrzyn K; Zhukov I; Maszota-Zieleniak M; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic deletion of HVEM in a leukemia B cell line promotes a preferential increase of PD-1
    Del Rio ML; de Juan CY; Roncador G; Caleiras E; Álvarez-Esteban R; Pérez-Simón JA; Rodriguez-Barbosa JI
    Front Immunol; 2023; 14():1113858. PubMed ID: 37033927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway.
    Cheung TC
    Recent Pat DNA Gene Seq; 2009; 3(3):177-82. PubMed ID: 19702559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia.
    Sordo-Bahamonde C; Lorenzo-Herrero S; Gonzalez-Rodriguez AP; R Payer Á; González-García E; López-Soto A; Gonzalez S
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33917094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
    Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
    J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice.
    Aubert N; Brunel S; Olive D; Marodon G
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of herpes virus entry mediator expression in hepatitis B virus-related hepatocellular carcinoma.
    Yi Y; Ni XC; Liu G; Yin YR; Huang JL; Gan W; Zhou PY; Guan RY; Zhou C; Sun BY; Qiu SJ
    Oncol Lett; 2020 Oct; 20(4):19. PubMed ID: 32774492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T Cells Expressing CAR Equipped With Extracellular Domain of BTLA Are Effective Against HVEM-over-expressing Melanoma Cell Lines.
    Kim Y; Kim JE; Lee DY; Choi JU; Park JS; Lee HK; Choi SU; Park S; Park CH
    Anticancer Res; 2023 Aug; 43(8):3419-3427. PubMed ID: 37500142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
    Cai G; Freeman GJ
    Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epitope topography of agonist antibodies to the checkpoint inhibitory receptor BTLA.
    Cheung TC; Atwell S; Bafetti L; Cuenca PD; Froning K; Hendle J; Hickey M; Ho C; Huang J; Lieu R; Lim S; Lippner D; Obungu V; Ward-Kavanagh L; Weichert K; Ware CF; Vendel AC
    Structure; 2023 Aug; 31(8):958-967.e3. PubMed ID: 37279757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.